Adjuvant Anti-PD-1 Boosts OS in Matched Melanoma Cases
TOPLINE Adjuvant anti-PD-1 therapy was associated with higher 5-year overall survival (OS) in patients with resected stage III melanoma than in matched untreated patients. However, at the population level, no survival difference was observed after adjuvant …